Review





Similar Products

94
Bio-Techne corporation recombinant human il-28b/ifn-lambda 3 protein
Recombinant Human Il 28b/Ifn Lambda 3 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il-28b/ifn-lambda 3 protein/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
recombinant human il-28b/ifn-lambda 3 protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
MedChemExpress recombinant opn protein
Recombinant Opn Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant opn protein/product/MedChemExpress
Average 94 stars, based on 1 article reviews
recombinant opn protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Proteintech humankine recombinant human hgf protein gmp grade
Humankine Recombinant Human Hgf Protein Gmp Grade, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/humankine recombinant human hgf protein gmp grade/product/Proteintech
Average 94 stars, based on 1 article reviews
humankine recombinant human hgf protein gmp grade - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
New England Biolabs recombinant proteins fetuin a
Recombinant Proteins Fetuin A, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant proteins fetuin a/product/New England Biolabs
Average 94 stars, based on 1 article reviews
recombinant proteins fetuin a - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

98
MedChemExpress recombinant tgf β1 protein
Recombinant Tgf β1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant tgf β1 protein/product/MedChemExpress
Average 98 stars, based on 1 article reviews
recombinant tgf β1 protein - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier

95
MedChemExpress recombinant proteins a 1331852 inhibitor medchemexpress cat
Recombinant Proteins A 1331852 Inhibitor Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant proteins a 1331852 inhibitor medchemexpress cat/product/MedChemExpress
Average 95 stars, based on 1 article reviews
recombinant proteins a 1331852 inhibitor medchemexpress cat - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

94
Sino Biological recombinant human cd38
A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
Recombinant Human Cd38, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human cd38/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human cd38 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Sino Biological recombinant human 289 egfr protein
A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
Recombinant Human 289 Egfr Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human 289 egfr protein/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human 289 egfr protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


A A schematic showing interaction between CLL1.CAR and CD38.SSR. CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).

Journal: Nature Communications

Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

doi: 10.1038/s41467-025-65897-4

Figure Lengend Snippet: A A schematic showing interaction between CLL1.CAR and CD38.SSR. CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).

Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

Techniques: Expressing, Transduction, Co-Culture Assay, Knock-Out

A Schematic illustration (left) and representative images (right) of calcium influx (green) in T cells (blue) at pre-contact or post-contact with Molm13 (red) over the indicated time course. B Calcium (Ca++) flux in T cells interacting with Molm13 over the indicated timepoints, and the mean area under the curve (AUC) for the initial 30 min post-contact. Each dot represents a single cell. Data include single cells (42 cells (NT), 34 cells (CAR), 30 cells (CAR + ΔSSR), 30 cells (CAR + SSR)) combined from 3 independent donors and experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Dot plots show mean + S.E.M. (* P < 0.05, ** P < 0.01, ns, non-significant). C Western blots showing the detection of phospho-proteins and GAPDH harvested from CAR or CAR.SSR T cells stimulated with plate-coated anti-CLL1 CAR antibody and recombinant CD38 at indicated time points. Data were repeated in three independent experiments using 3 donors. MW, molecular weight. D Densitometry analysis of pPLCγ1, pERK1/2 and pNF-KB normalized to GAPDH. E Schematic of an SSR construct containing a point mutation Y132F in the LAT endo-domain, and flow plots (bottom) showing the co-expression of CAR and SSR or SSR with Y132F on day 6 post transduction. F Residual tumor counts (left) and T-cell expansion normalized to day 0 (right) in a 3 day co-culture with Molm13. Data represent two independent experiments with 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ns, non-significant).

Journal: Nature Communications

Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

doi: 10.1038/s41467-025-65897-4

Figure Lengend Snippet: A Schematic illustration (left) and representative images (right) of calcium influx (green) in T cells (blue) at pre-contact or post-contact with Molm13 (red) over the indicated time course. B Calcium (Ca++) flux in T cells interacting with Molm13 over the indicated timepoints, and the mean area under the curve (AUC) for the initial 30 min post-contact. Each dot represents a single cell. Data include single cells (42 cells (NT), 34 cells (CAR), 30 cells (CAR + ΔSSR), 30 cells (CAR + SSR)) combined from 3 independent donors and experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Dot plots show mean + S.E.M. (* P < 0.05, ** P < 0.01, ns, non-significant). C Western blots showing the detection of phospho-proteins and GAPDH harvested from CAR or CAR.SSR T cells stimulated with plate-coated anti-CLL1 CAR antibody and recombinant CD38 at indicated time points. Data were repeated in three independent experiments using 3 donors. MW, molecular weight. D Densitometry analysis of pPLCγ1, pERK1/2 and pNF-KB normalized to GAPDH. E Schematic of an SSR construct containing a point mutation Y132F in the LAT endo-domain, and flow plots (bottom) showing the co-expression of CAR and SSR or SSR with Y132F on day 6 post transduction. F Residual tumor counts (left) and T-cell expansion normalized to day 0 (right) in a 3 day co-culture with Molm13. Data represent two independent experiments with 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ns, non-significant).

Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

Techniques: Western Blot, Recombinant, Molecular Weight, Construct, Mutagenesis, Expressing, Transduction, Co-Culture Assay

A Representative flow plots showing expression of CD38 and CLL1 in PBMCs including CD14+ monocytes, CD3 + T cells, CD3-CD56 + NK cells and CD19 + B cells. B Residual PBMCs after a 24-h co-culture with autologous T cells at a 1:4 E:T ratio. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (** P < 0.01. ns, non-significant). C Quantification of a burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte/macrophage (CFU-GM) from hematopoietic stem cells/progenitors (HSPC) after 5-h co-culture of indicated CAR T cells with CD34+ cord blood cells at a E:T ratio 10:1, and expanded for 12 days in semi-solid methylcellulose. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Flow histograms show surface CLL1 and CD38 levels on AML blasts (CD33 + /CD34 + ) from the PBMCs collected from 2 patients (Pt1 and Pt2). E The residual AML blasts were detected at 24 h or 72 h after co-culture with CLL1 CAR T cells at a 1:1 E:T ratio. Data represent 3 independent donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons, or two-tailed, paired Student’s t test for CAR vs CAR + SSR in residual AML blasts from Pt2 at 72 h. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant).

Journal: Nature Communications

Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

doi: 10.1038/s41467-025-65897-4

Figure Lengend Snippet: A Representative flow plots showing expression of CD38 and CLL1 in PBMCs including CD14+ monocytes, CD3 + T cells, CD3-CD56 + NK cells and CD19 + B cells. B Residual PBMCs after a 24-h co-culture with autologous T cells at a 1:4 E:T ratio. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (** P < 0.01. ns, non-significant). C Quantification of a burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte/macrophage (CFU-GM) from hematopoietic stem cells/progenitors (HSPC) after 5-h co-culture of indicated CAR T cells with CD34+ cord blood cells at a E:T ratio 10:1, and expanded for 12 days in semi-solid methylcellulose. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Flow histograms show surface CLL1 and CD38 levels on AML blasts (CD33 + /CD34 + ) from the PBMCs collected from 2 patients (Pt1 and Pt2). E The residual AML blasts were detected at 24 h or 72 h after co-culture with CLL1 CAR T cells at a 1:1 E:T ratio. Data represent 3 independent donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons, or two-tailed, paired Student’s t test for CAR vs CAR + SSR in residual AML blasts from Pt2 at 72 h. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant).

Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

Techniques: Expressing, Co-Culture Assay, Two Tailed Test

A A schematic showing enhancement of cytotoxicity of survivin-specific TCR (Sur-TCR) by a CD38.SSR. B Representative flow plots showing co-expression of Sur-TCR and SSR on day 7 post-transduction (TD), and ( C ) expansion of TCR T cells derived from 3 HLA-A2- and 3 HLA-A2+ donors on day 10. Data represent 6 donors from two independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (ns, non-significant). D Histograms showing intracellular survivin, surface HLA-A2 and CD38 levels in leukemia cell lines BV173, THP1 and TALL1. E Residual tumor counts after a 3-day co-culture with Sur-TCR T cells at a 1:4 E:T ratio. Data represent 6 donors from two independent experiments in co-culture with BV173 and THP1, and 3 donors from one independent experiment in co-culture with TALL1. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). Percentages of ( F ) granzyme B/CD107a double positive T cells and ( G ) cytokine positive T cells after 4-h co-culture with indicated leukemia cells at 1:1 E:T ratio. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). H Schematic timeline of the mouse experiment. I Leukemia progression was monitored by bioluminescence. J Tumor burden AUC between day 0 and day 26. The data represent 5 mice in NT and 4 mice in for TCR, TCR.ΔSSR and TCR.SSR. P values were determined using one-way ANOVA with Dunnet’s correction for multiple comparisons compared to NT. Bar graphs show mean + S.E.M. (* P = 0.0394). K Overall mouse survival in the THP1 model (NT, n = 5, TCR, n = 5, TCR.ΔSSR, n = 5, TCR.SSR, n = 4). Statistical significance was determined by a log rank test. (* P = 0.0214).

Journal: Nature Communications

Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

doi: 10.1038/s41467-025-65897-4

Figure Lengend Snippet: A A schematic showing enhancement of cytotoxicity of survivin-specific TCR (Sur-TCR) by a CD38.SSR. B Representative flow plots showing co-expression of Sur-TCR and SSR on day 7 post-transduction (TD), and ( C ) expansion of TCR T cells derived from 3 HLA-A2- and 3 HLA-A2+ donors on day 10. Data represent 6 donors from two independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (ns, non-significant). D Histograms showing intracellular survivin, surface HLA-A2 and CD38 levels in leukemia cell lines BV173, THP1 and TALL1. E Residual tumor counts after a 3-day co-culture with Sur-TCR T cells at a 1:4 E:T ratio. Data represent 6 donors from two independent experiments in co-culture with BV173 and THP1, and 3 donors from one independent experiment in co-culture with TALL1. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). Percentages of ( F ) granzyme B/CD107a double positive T cells and ( G ) cytokine positive T cells after 4-h co-culture with indicated leukemia cells at 1:1 E:T ratio. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). H Schematic timeline of the mouse experiment. I Leukemia progression was monitored by bioluminescence. J Tumor burden AUC between day 0 and day 26. The data represent 5 mice in NT and 4 mice in for TCR, TCR.ΔSSR and TCR.SSR. P values were determined using one-way ANOVA with Dunnet’s correction for multiple comparisons compared to NT. Bar graphs show mean + S.E.M. (* P = 0.0394). K Overall mouse survival in the THP1 model (NT, n = 5, TCR, n = 5, TCR.ΔSSR, n = 5, TCR.SSR, n = 4). Statistical significance was determined by a log rank test. (* P = 0.0214).

Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

Techniques: Expressing, Transduction, Derivative Assay, Co-Culture Assay